Aspen Pharmacare (OTCMKTS:APNHY) – Equities researchers at Jefferies Group lifted their FY2022 earnings per share (EPS) estimates for shares of Aspen Pharmacare in a report issued on Wednesday. Jefferies Group analyst J. Vane-Tempest now expects that the company will earn $2.14 per share for the year, up from their prior forecast of $2.00.
Separately, Zacks Investment Research raised Aspen Pharmacare from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Thursday, October 26th.
COPYRIGHT VIOLATION WARNING: “FY2022 Earnings Estimate for Aspen Pharmacare Issued By Jefferies Group (APNHY)” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3147713/fy2022-earnings-estimate-for-aspen-pharmacare-issued-by-jefferies-group-apnhy.html.
Aspen Pharmacare Company Profile
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies branded and generic pharmaceutical products, infant nutritionals, and consumer healthcare products. The company offers various branded products for a range of therapeutic categories, including anaesthetics, analgesics, anti-retrovirals, blood and haemopoetic, cardio vascular system, central nervous system, endocrine system, gastro-intestinal tract, infant milk formulations, musculo-skeletal agents, NSAIDs, oncology, oral hygiene, respiratory system, and urinary tract system, as well as ear, nose, and throat.
Receive News & Ratings for Aspen Pharmacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacare and related companies with MarketBeat.com's FREE daily email newsletter.